SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Clinical trial NCT06325748 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06325748
Sponsor: Senti Biosciences
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

AML/MDS CD33 Expressing Hematological Malignancies FLT3 Expressing Hematological Malignancies

Start date: 2024-04-22
Primary completion: 2026-02-01
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.